FDA approved enzalutamide (XTANDI, Astellas Pharma Inc.)

FDA approved enzalutamide (XTANDI, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC). More Information. December 16, 2019

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer

 Hematology/Oncology (Cancer) Approvals & Safety Notifications 
 
 

© 2021 FLASCO | Premium Website Design by The HDG

FLASCO